Evidence map›Paper›PMID 41726328›Full record

ArticleACS bio & med chem Au2026

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [

Brooke L McNeil, Luke Wharton, Chao-Cheng Chen, Helen Merkens, Milena Čolović, Cristina Rodríguez-Rodríguez, John Wilson, Stefan Mair, Chengcheng Zhang, Anthony W McDonagh and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS bio & med chem Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Brooke L McNeilDepartment of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.
Luke WhartonLife Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada.ORCID https://orcid.org/0000-0002-0636-8741
Chao-Cheng ChenDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.ORCID https://orcid.org/0000-0003-2685-6766
Helen MerkensDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
Milena ČolovićLife Sciences Division, TRIUMF, Vancouver, British Columbia V6T 2A3, Canada.ORCID https://orcid.org/0000-0001-8686-0084
Cristina Rodríguez-RodríguezFaculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, British Columbia V6T 1Z3, Canada.ORCID https://orcid.org/0000-0002-3313-4422
John WilsonDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada.
Stefan MairDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
Chengcheng ZhangDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
Anthony W McDonaghDepartment of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.
Kuo-Shyan LinDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.ORCID https://orcid.org/0000-0002-0739-0780
François BénardDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.ORCID https://orcid.org/0000-0001-7995-3581
Frank WuestDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada.ORCID https://orcid.org/0000-0002-6705-6450
Paul SchafferDepartment of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.ORCID https://orcid.org/0000-0002-6392-8792
Caterina F RamogidaDepartment of Chemistry, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada.ORCID https://orcid.org/0000-0003-4815-2647

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is overexpressed in a variety of cancers, making it an attractive target for bifunctional chelator-based radiopharmaceuticals. This study initially aimed to assess the effect of chelator structure on the biodistribution of

Indexed as

amideFAPIlead-203lead-212MC1Rtheranosticsthiourea

Identifiers

PMID41726328
PMCPMC12921517

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.